Scott Praill insider trades: Kintara Therapeutics (KTRA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 8, 2021 | KTRA | ↑ Buy | 28,700 | $0.68 | $19K | Direct | Dec 9, 2021 (1d) |
| Oct 5, 2017 | DMPI | ↑ Buy | 17,500 | $0.85 | $15K | Direct | Oct 5, 2017 (0d) |
| Jun 26, 2017 | DMPI | ↑ Buy | 4,167 | $3.60 | $15K | Direct | Jun 28, 2017 (2d) |
| Jun 6, 2017 | DMPI | ↑ Buy | 9,500 | $2.10 | $20K | Direct | Jun 6, 2017 (0d) |
| Jul 16, 2015 | DMPI | ↑ Buy | 50,000 | $0.60 | $30K | Direct | Jul 16, 2015 (0d) |
| Mar 18, 2014 | DMPI | ↑ Buy | 10,000 | $1.30 | $13K | Direct | Mar 20, 2014 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Scott Praill's insider trades
Scott Praill is Chief Financial Officer at Kintara Therapeutics (KTRA). Since Mar 18, 2014, Scott has reported 6 open-market purchases worth $112K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include other transactions (23 filings), grants and awards (7 filings), conversions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KTRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.